<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630876</url>
  </required_header>
  <id_info>
    <org_study_id>YUH-12-0309-M2</org_study_id>
    <nct_id>NCT01630876</nct_id>
  </id_info>
  <brief_title>Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane</brief_title>
  <official_title>Anatomic and Functional Outcomes of 23-gauge Vitrectomy Combined With Posterior Subtenon Triamcinolone Injection for the Treatment of Idiopathic Epiretinal Membrane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yeungnam University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yeungnam University College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the anatomical and visual outcomes of patients with idiopathic epiretinal
      membrane(ERM) treated by vitrectomy and membrane peeling with or without subtenon
      triamcinolone acetonide injection
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of best corrected visual acuity and central retinal thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Changes of best corrected visual acuity and central retinal thickness on optical coherence tomography (OCT) at baseline and 1, 3, 6 months after injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in status of ISOS line</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in status of ISOS line on optical coherence tomography (OCT) at baseline and 1, 3, 6 months after injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Epiretinal Membrane</condition>
  <arm_group>
    <arm_group_label>Vitrectomy only group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy only group</intervention_name>
    <description>The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.</description>
    <arm_group_label>Vitrectomy only group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combined therapy group</intervention_name>
    <description>The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.</description>
    <arm_group_label>Combined therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.The participant must have idiopathic epiretinal membrane 2.The participant must be
             willing and able to comply with the protocol.

        Exclusion Criteria:

          -  1. The participant has idiopathic epiretinal membrane with other ocular vascular
             diseases such as Diabetes retinopathy, BRVO, etc.

             2. The participant has any additional ocular diseases that have irreversibly
             compromised or could likely compromise the visual acuity of the study eye including
             amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular
             edema, severe non proliferative diabetic retinopathy, or proliferative diabetic
             retinopathy.

             3. The participant has had intraocular surgery (including lens replacement surgery).

             4. The participant has a history of (within the last six months), or current ocular or
             periocular infection (including any history of ocular herpes zoster or simplex).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yeungnam University College of Medicine</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Sagong</last_name>
      <phone>82-53-620-4191</phone>
      <email>msagong@ynu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Min Sagong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>October 1, 2012</last_update_submitted>
  <last_update_submitted_qc>October 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yeungnam University College of Medicine</investigator_affiliation>
    <investigator_full_name>Min Sagong</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Epiretinal membrane</keyword>
  <keyword>triamcinolone acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epiretinal Membrane</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

